

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 31/00, 31/405	A1	(11) International Publication Number: WO 93/24115 (43) International Publication Date: 9 December 1993 (09.12.93)
(21) International Application Number: PCT/CA92/00229 (22) International Filing Date: 29 May 1992 (29.05.92)		(74) Agent: BARRIGAR & OYEN; #480 - The Station, 601 West Cordova Street, Vancouver, British Columbia V6B 1G1 (CA).
(71) Applicant: THE UNIVERSITY OF BRITISH COLUMBIA [CA/CA]; Research Administration, Room 331, IRC Building, 2194 Health Sciences Mall, Vancouver, British Columbia V6T 1W5 (CA).		(81) Designated States: JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE).
(72) Inventors: MCGEER, Patrick. L. ; 4727 West 2nd Avenue, Vancouver, British Columbia V6T 1C1 (CA). ROGERS, Joseph ; 7646 W. Julie Driv., Glendale, AZ 85308 (US). SIBLEY, John ; 87 Leddy Crescent, Saskatoon, Saskatchewan S7H 3Y9 (CA). MCGEER, Edith, G. ; 4727 West 2nd Avenue, Vancouver, British Columbia V6T 1C1 (CA).		Published <i>With international search report.</i> <i>With amended claims.</i>

(54) Title: ANTI-RHEUMATOID ARTHRITIC DRUGS IN THE TREATMENT OF DEMENTIA

(57) Abstract

This invention pertains to the novel use of anti-rheumatoid arthritic drugs in the treatment of dementia. A method of treating dementia in human beings characterized by administering to the human being a therapeutic amount of a non-steroidal anti-inflammatory drug (NSAID) which has the ability to inhibit prostaglandin synthesis in the human being.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BC	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CC	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LK	Liechtenstein	SN	Senegal
CM	Cameroon	LJ	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
C2	Czech Republic	MC	Monaco	TC	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	MN	Mali	US	United States of America
ES	Spain		Mongolia	VN	Viet Nam
FI	Finland				

- 2 -

used NSAID, showed little or no mental deterioration. NSAIDs are relatively safe agents. While they all have side effects, such side effects are well known due to their very extensive use in a wide range of inflammatory diseases 5 where long term treatment is common.

The invention pertains to a method of treating dementia in human beings characterized by administering to the human being a therapeutic amount of a substance selected from the non-steroidal anti-inflammatory group of cyclooxygenase inhibitors.

The invention also pertains to a composition for treating dementia in human beings which composition is 15 characterized by a substance or substances selected from the group consisting of non-steroidal anti-inflammatory cyclooxygenase inhibitors, therapeutically acceptable salts thereof, and therapeutically acceptable carriers.

20 The invention also pertains to an article of manufacture characterized by packaging material and a pharmaceutical agent contained within said packaging material, wherein the pharmaceutical agent is therapeutically effective for treating dementia in human beings, and 25 wherein the packaging material is characterized by a notification which indicates that the pharmaceutical agent can be used for the treatment of dementia, and wherein said pharmaceutical agent is characterized by a therapeutically effective amount of a non-steroidal anti-inflammatory drug 30 which has the ability to inhibit prostaglandin synthesis in the human being.

Within the terms of the invention, the NSAIDs include, but are not restricted to, the following chemical 35 agents that inhibit prostaglandin synthesis primarily by their activity against the enzyme cyclooxygenase:

- 3 -

- 5 (1) Arylcarboxylic acids: salicylic acid, acetyl-salicylic acid, diflunisal, choline magnesium trisalicylate, salicylate, benorylate, flufenamic acid, mefenamic acid, meclofenamic acid, niflumic acid;
- 10 (2) Arylalkanoic acids: diclofenac, fenclofenac, alclofenac, fentiazac, ibuprofen, flurbiprofen, ketoprofen, naproxen, fenoprofen, fenbufen, suprofen, indoprofen, tiaprofenic acid, benoxaprofen, pirprofen, tolmetin, zomepirac, clopinac, indomethacin, sulindac;
- 15 (3) Enolic acids: phenylbutazone, oxyphenbutazone, azapropazone, feprazole, piroxicam, isoxicam, sudoxicam.

20 The dosage of each agent will vary. For each patient, it will be the dosage that is required to inhibit effectively prostaglandin synthesis *in vivo*, but not to induce unwanted side effects such as gastrointestinal bleeding. Daily doses of an agent can range from 10 mg to 3 g per 100 kg body weight.

25 The composition can be characterized by a NSAID cyclooxygenase inhibitor and a therapeutically acceptable carrier. The substance can be present in the composition at a dosage of 5 mg to 1 gm.

30

DRAWINGS

In the drawings:

35 Figure 1 illustrates a graphical depiction of Mini-Mental Status test results plotted by change of score against months of treatment.

- 4 -

Figure 2 illustrates a graphical depiction of Alzheimer's Assessment Scale test results plotted by change of score against months of treatment.

5 Figure 3 illustrates a graphical depiction of Boston Naming Test test results plotted by change of score against months of treatment.

10 Figure 4 illustrates a graphical depiction of Token Test test results plotted by change of score against months of treatment.

DETAILED DESCRIPTION OF A
PREFERRED EMBODIMENT OF THE INVENTION

15 We have conducted research which has demonstrated that changes characteristic of an inflammatory process occur in Alzheimer brain tissue. The cellular and protein alterations that we have observed are similar to those seen
20 in other tissues of the body in diseases where there is an autoimmune disorder, or a persistent, non-lethal pathogen. Rheumatoid arthritis is typical of such diseases. Such diseases respond to a variety of anti-inflammatory agents, which have in common the ability to inhibit cells which
25 attack the human body's own tissues. Based on this research and not wishing to be adversely bound by any theories, we have reasoned that rheumatoid arthritics, who require long term treatment with such agents to keep immune system cells from attacking the joint tissue, would be
30 spared from Alzheimer's disease because such immune system cells would be similarly inhibited from attacking their brain tissue. We have further reasoned that Alzheimer disease can be effectively treated with any drug of the NSAID class since drugs of this class are almost universally prescribed at some stage in rheumatoid arthritis.
35

- 5 -

We have conducted a survey of patients suffering from rheumatoid arthritis to determine the prevalence of Alzheimer disease in such patients. We have found that the prevalence is dramatically lower than the prevalence of dementia in the age-matched general population. The prevalence of Alzheimer disease in the age group 65 years and over in North America is reported to be from 2.5 to 10.3%, depending on the survey (Evans, D.A., Funkenstein, H.H., Albert, M.S. et al. Prevalence of Alzheimer Disease 5 in a community population of older persons. JAMA 1989; 10 262: 2551-2556; Mortimer, J.A. Alzheimer's Disease and dementia: prevalence and incidence. In: Reisberg, B. (ed.) Alzheimer's Disease, Glencoe, Free Press, 1983; Sulkava, R., Wikstrom, J., Aromaa, A. et al. Prevalence of severe 15 dementia in Finland. Neurology 1985; 35: 1025-1029). We have found unexpectedly that the prevalence of Alzheimer disease amongst rheumatoid arthritics 65 years or over is only 0.39% (29/7,490). This is roughly 6 to 26 fold lower 20 in level of prevalence. It is not possible to relate this reduction to any single anti-arthritis drug since patients suffering from rheumatoid arthritis are typically treated with one or more of a variety of anti-inflammatory drugs, with the dose being titrated to produce the best control 25 for each person. However, almost all will have been treated at some stage of their disease with one or more NSAIDs.

Immunohistochemical evidence points to a chronic inflammatory state of the brain in Alzheimer dementia (AD). 30 T4 and T8 lymphocytes and reactive microglia strongly expressing major histocompatibility complex (MHC) surface glycoproteins, are found in plaque and tangle lesions (Itagaki, S., McGeer, P.L., Akiyama, H. Presence of T-cytotoxic suppressor and leucocyte common antigen positive 35 cells in Alzheimer's Disease brain tissue. Neurosci. Lett. 1988; 91: 259-264; Rogers, J., Luber-Narod, J., Styren, S.D., Civin, W.H. Expression of immune system-associated

- 6 -

antigen by cells of the human central nervous system. Relationship to the pathology of Alzheimer's Disease. Neurobiol. Aging, 1988; 9: 330-349; McGeer, P.L., Akiyama, H., Itagaki, S., McGeer, E.G. Immune system response in 5 Alzheimer's Disease. Can. J. Neurol. Sci. 1989; 16: 516-527; McGeer, P.L., Akiyama, H., Itagaki, S., McGeer, E.G. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 1989; 107: 341-346; McGeer, P.L., McGeer, E.G., Rogers, J., Sibley, 10 J. Anti-inflammatory drugs and Alzheimer's Disease. Lancet 1990; 335: 1037). Cell membranes of reactive microglia are densely occupied by complement receptors, and degenerating elements are stained by antibodies to complement proteins. Cell lysis and opsonization of debris seems 15 to be taking place (McGeer et al., Immune system response in Alzheimer's disease; McGeer et al., Activation of the classical complement pathway in brain tissue of Alzheimer patients). Long-term anti-inflammatory chemical therapy might therefore retard the development of Alzheimer disease. One test of this hypothesis is to compare the 20 prevalence of Alzheimer disease in the general population with the prevalence in patients with rheumatoid arthritis (RA), since such patients generally receive anti-inflammatory therapy and often contract arthritis well before the 25 age of risk for Alzheimer disease (McGeer et al., Anti-inflammatory drugs and Alzheimer's disease).

Example 1

30 The applicants have examined four types of prevalence data as set out in Table 1 below: rheumatoid arthritis in Alzheimer disease cases coming to necropsy, Alzheimer disease in rheumatoid arthritis clinic patients, rheumatoid arthritis in Alzheimer disease clinic patients, 35 and rheumatoid arthritis coincident with Alzheimer disease in separation data for general hospitals.

ANTI-RHEUMATOID ARTHRITIC DRUGS IN
THE TREATMENT OF DEMENTIA

This invention pertains to the novel use of non-
5 steroidal anti-inflammatory drugs in the treatment of dementia (Alzheimer disease) in human beings.

Non-steroidal anti-inflammatory drugs (NSAIDs) are the drugs of choice for the treatment of rheumatoid 10 arthritis (Textbook of Rheumatology, eds. Kelley, W.N., Harris, E.D. Jr., Ruddy, S., Sledge, C.B., Saunders Co., 1989). They have fewer side effects than other classes of anti-arthritis drugs and are therefore almost universally prescribed for this condition. They are characterized by 15 their ability to inhibit prostaglandin synthesis through anti-cyclooxygenase activity. They can be classified chemically as derivatives of arylcarboxylic acids, including salicylic and anthranilic acid derivatives; aryl-alkanoic acids, including arylacetic, arylpropionic, 20 heteroarylacetic, indoleacetic and indeneacetic acids; and enolic acids, including pyrazolidinediones and oxicams.

While drugs in this class are among the most widely used in medicine, there is no literature or teaching 25 in the art to indicate that any NSAID has been used in the treatment of Alzheimer's disease (dementia). This brain disorder is estimated to affect 0.5-1% of the general population in industrialized countries and threatens to become more prevalent as the average age of the human 30 population increases.

SUMMARY OF THE INVENTION

We have determined that patients with rheumatoid 35 arthritis, most of whom will have been treated with one or more of these agents, have a much lower prevalence of Alzheimer disease than the age-matched general population. We have also determined in a 6 month pilot trial, and other trials, that Alzheimer cases given indomethacin, a widely

- 7 -

Table 1
Patients Over Age 64 with Diagnosis of
Rheumatoid Arthritis and Alzheimer Disease

	<u>Data Source</u>	<u>RA</u>	<u>AD</u>	<u>Both</u>
	Necropsy			
	B.C.	--	107	2
	Arizona	--	62	0
10	RA Clinics			
	Saskatchewan	815	--	4
	Arizona	105	--	0
15	AD Clinics			
	B.C.	--	317	1
	Arizona	--	92	1
20	General Hospitals			
	B.C.	2261	1960	16
	Ontario	3987	3073	12
	Alberta	375	30	0
	Arizona	867	693	1
25	Total	(7490)	(5757)	(29)

Necropsy Data

In the records of 169 consecutive necropsy cases of dementia with some evidence of plaque and tangle lesions we found only two with an antecedent history of RA, and in neither were the necropsy findings typical of AD.

RA Clinic Data

We next reviewed data from RA clinics where patients had been followed-up regularly for a long time. Of 923 patients over 64, only four had clinical signs of AD; all four are still living so AD has not been confirmed.

AD Clinic Data

Of 409 patients with clinically diagnosed AD, only two had RA; one had acquired RA concomitantly with AD while the other was one of the atypical necropsy cases noted above.

Separation Statistics

5 We examined data on patients over the age of 64 who were in general hospitals with diagnoses of AD, RA or both. 0.39% of those with a diagnosis of RA were recorded as having AD, and 0.50% of those with probable AD had RA, the double diagnosis affecting 29 patients.

10 The prevalences found in the RA clinic and general hospital populations (see Table 1) are dramatically lower than the 2.5-10.3% reported for the over 64 North American population. Epidemiological data on RA are less well documented but a prevalence of at least 2% is likely for the age group we have been studying, and the prevalence 15 we found in AD populations is therefore significantly less than expected.

20 Four possible interpretations of the observed low prevalence of coexisting AD and RA can be postulated:

(1) The reported prevalences for both AD and RA diseases in the general population are several times too high (but this seems unlikely).

25 (2) Only a small minority of patients having coexisting diseases were diagnosed as such. Since AD and RA have prominent symptoms, this interpretation seems unlikely, at least for the clinic populations.

30 (3) AD develops less often in the RA population, but this is unrelated to the long term administration of anti-inflammatory drugs. (This postulation seems unlikely.)

35 (4) Anti-inflammatory drug therapy confers some protection against the occurrence of AD. A detailed review of the charts of all 23 patients in British Columbia and

- 9 -

Saskatchewan who had both diseases revealed six cases with onset of dementia at ages 62, 66, 79, 86, 93 and 96, many years after discontinuing anti-inflammatory medications; one case of RA after the onset of dementia; one case with 5 no history of anti-inflammatory treatment and development of both diseases at age 79; seven cases without clear records; and seven cases on long-term anti-inflammatory treatment.

10 The above data suggest that the prevalence of Alzheimer disease in patients with rheumatoid arthritis being treated by anti-inflammatory drugs is dramatically lower than in the age-matched general population and that anti-inflammatory medication is the probable reason.

15 To test further the validity of this theory, we selected one NSAID, indomethacin, and administered it to a group of five clinically diagnosed early Alzheimer cases in an open, six month trial. All had been diagnosed as 20 having AD and all were re-evaluated and the AD diagnosis confirmed by two board certified neurologists immediately before the drug trials began. Patients received four neuropsychological tests before drug administration: the Mini Mental Status Exam (Figure 1), the Alzheimer Disease 25 Assessment Scale (Figure 2), the Boston Naming Test (Figure 3), and the Token Test (Figure 4). Neuropsychologists were blind to patient drug treatment throughout. The five patients received indomethacin according to the following regimen: 50 mg/day for week one, 100 mg/day for week two, 30 150 mg/day for the remainder of the six month trial. Indomethacin was administered daily in three divided doses. One patient was living independently and could not remember to take her medicine. She was removed from the study after one month on the drug. Another patient developed gastro- 35 intestinal bleeding after five months on the drug; indomethacin was withdrawn but her test scores at baseline, three months and six months are included in the analysis.

- 10 -

The Mini Mental Status Exam and the Alzheimer Disease Assessment Scale (ADAS) were repeated at three months and six months. The Boston Naming Test and Token Test were repeated at six months only. Scores plotted on the graphs 5 (Figures 1, 2, 3 and 4) are differences from baseline measures, with improvement always showing as upward lines and decrements as downward lines.

10 The data for the group show almost no change on the Mini Mental Status Exam, a slight improvement on the Boston Naming Test, and slight decrements on the Alzheimer Assessment Scale and the Token Test. Without treatment, significant declines would have been anticipated in all of these tests over a period of six months.

15

Example 2

Recent data shows a significant beneficial therapeutic impact of an NSAID, indomethacin, on 20 Alzheimer's disease. The results summarized below are from an ongoing double-blind, placebo-controlled study of indomethacin (Indocin) versus placebo for a treatment period of 6 months. A total of 50 clinically confirmed Alzheimer's disease patients with Mini-Mental Status Test 25 (MMSE) scores equal to or greater than 16 were enrolled. Of those, a total of 21 (11 indomethacin and 10 placebo) patients had completed the trial by the time an investigator not involved with clinical or neuropsychological evaluation of the patients broke the code for drug treatment 30 of the 21 patients and analyzed the resulting data. Four tests of mental status were employed, the MMSE, Alzheimer's Disease Assessment Scale (ADAS), Boston Naming Test (BNT), and Token Test (TT). These tests were administered to all patients immediately before being placed on 35 indomethacin (100-150 mg per day, depending on weight, in three divided doses) or placebo and after 6 months of treatment. The data were evaluated using the percentage

- 11 -

change from baseline after 6 months of treatment. A repeated measures analysis of variance of these data (with drug treatment as the grouping factor and mental status test as the repeated measures factor) showed a significant
5 therapeutic effect of indomethacin compared to placebo ($F_{1,19} = 4.505$, $P < .05$). These results suggest a very robust effect of indomethacin since it has been estimated that inherent variability of mental status scores in Alzheimer's patients might require a test of 200 patients
10 for 2 years in order to demonstrate efficacy of a drug treatment for Alzheimer's disease.

A recent discovery by the applicants shows that the immune mechanism against which NSAIDs are to be applied
15 for Alzheimer's dementia are novel and unexpected. That is, the applicants have found that β -amyloid, a peptide that is excessively deposited in the Alzheimer's disease brain, binds the complement protein Clq and activates the classical complement pathway in vitro. This finding is
20 completely unexpected, completely original to the applicants, and provides a new and novel basis for why NSAIDs should be of therapeutic value in the treatment of Alzheimer's disease dementia.

25 To the applicants' knowledge, there has been no previous trial of NSAIDs for dementia, save their own, precisely because it was so unexpected by other investigators that such a trial would be warranted, much less successful.

- 12 -

WHAT IS CLAIMED IS:

1. A method of treating dementia in a human being characterized by administering to the human being a therapeutic amount of a non-steroidal anti-inflammatory drug which has the ability to inhibit prostaglandin synthesis in the human being.
2. A method as claimed in claim 1 wherein the drug is selected from the group consisting of derivatives of arylcarboxylic acids, arylalkanoic acids and enolic acids, and therapeutically acceptable salts thereof.
3. A method as claimed in claim 2 wherein the arylcarboxylic acid is a salicylic acid or an anthranilic acid derivative; the arylalkanoic acid is arylacetic, arylpropionic, heteroarylacetate, indoleacetic or indene-acetic acid; and the enolic acid is pyrazolidinedione or oxicam, and therapeutically acceptable salts thereof..
4. A method of treating dementia in human beings characterized by administering to the human being a therapeutic amount of a substance selected from the group consisting of salicylic acid, acetylsalicylic acid, diflunisal, choline magnesium trisalicylate, salicylate, benorylate, flufenamic acid, mefenamic acid, meclofenamic acid, niflumic acid, diclofenac, fenclofenac, alclofenac, fentiazac, ibuprofen, flurbiprofen, ketoprofen, naproxen, fenoprofen, fenbufen, suprofen, indoprofen, tiaprofenic acid, benoxaprofen, pirprofen, tolmetin, zomepirac, clopinac, indomethacin, sulindac, phenylbutazone, oxyphenbutazone, azapropazone, feprazole, piroxicam, isoxicam and sodoxicam.
5. A method as claimed in claim 4 wherein the substance is administered in an amount required to inhibit effectively prostaglandin synthesis in vivo but avoid

- 13 -

inducing unwanted side effects such as gastrointestinal bleeding.

6. A method as claimed in claim 4 wherein the daily dosage is from 10 mg to 3 g of substance per 100 kg of body weight of the human being.

7. A method as claimed in claim 4 wherein the substance is indomethacin.

10 8. A composition for treating dementia in human beings characterized by a non-steroidal anti-inflammatory drug which was has the ability to inhibit prostaglandin synthesis in the human being, and therapeutically acceptable salts thereof, and a therapeutically acceptable carrier.

.20 9. A composition as claimed in claim 7 wherein the drug is selected from the group consisting of derivatives of arylcarboxylic acids, arylalkanoic acids and enolic acids, and therapeutically acceptable salts thereof, and a therapeutically acceptable carrier.

25 10. A composition as claimed in claim 8 wherein the arylcarboxylic acid is a salicylic acid or an anthranilic acid derivative; the arylalkanoic acid is arylacetic, arylpropionic, heteroarylacetic, indoleacetic or indene-acetic acid; and the enolic acid is pyrazolidinedione or oxicam, and therapeutically acceptable salts thereof, and 30 a therapeutically acceptable carrier.

35 11. A composition for treating dementia in human beings characterized by a therapeutic amount of a substance selected from the group consisting of salicylic acid, acetylsalicylic acid, diflunisal, choline magnesium trisalicylate, salicylate, benorylate, flufenamic acid, mefenamic acid, meclofenamic acid, niflumic acid, diclo-

- 14 -

- fenac, fenclofenac, alclofenac, fentiazac, ibuprofen,
flurbiprofen, ketoprofen, naproxen, fenoprofen, fenbufen,
suprofen, indoprofen, tiaprofenic acid, benoxaprofen,
pirprofen, tolmetin, zomepirac, clopinac, indomethacin,
5 sulindac, phenylbutazone, oxyphenbutazone, azapropazone,
feprazole, piroxicam, isoxicam and sudoxicam, and therapeu-
tically acceptable salts thereof, and a therapeutically
acceptable carrier.
- 10 12. A composition as claimed in claim 11 wherein the
therapeutic amount is from 10 mg to 3 g.
13. An article of manufacture characterized by
packaging material and a pharmaceutical agent contained
15 within said packaging material, wherein the pharmaceutical
agent is therapeutically effective for treating dementia in
human beings, and wherein the packaging material is charac-
terized by a notification which indicates that the pharma-
ceutical agent can be used for the treatment of dementia,
20 and wherein said pharmaceutical agent is characterized by
a therapeutically effective amount of a non-steroidal anti-
inflammatory drug which has the ability to inhibit prosta-
glandin synthesis in the human being.

AMENDED CLAIMS

[received by the International Bureau on 28 September 1993 (28.09.93);
original claims unchanged; new claims 14-18 added (2 pages)]

- fenac, fenclofenac, alclofenac, fentiazac, ibuprofen,
flurbiprofen, ketoprofen, naproxen, fenoprofen, fensufen,
suprofen, indoprofen, tiaprofenic acid, benoxaprofen,
pirprofen, tolmetin, zomepirac, clopinac, indomethacin,
5 sulindac, phenylbutazone, oxyphenbutazone, azapropazone,
feprazole, piroxicam, isoxicam and sudoxicam, and therapeu-
tically acceptable salts thereof, and a therapeutically
acceptable carrier.
- 10 12. A composition as claimed in claim 11 wherein the
therapeutic amount is from 10 mg to 3 g.
13. An article of manufacture characterized by
packaging material and a pharmaceutical agent contained
15 within said packaging material, wherein the pharmaceutical
agent is therapeutically effective for treating dementia in
human beings, and wherein the packaging material is charac-
terized by a notification which indicates that the pharma-
ceutical agent can be used for the treatment of dementia,
20 and wherein said pharmaceutical agent is characterized by
a therapeutically effective amount of a non-steroidal anti-
inflammatory drug which has the ability to inhibit prosta-
glandin synthesis in the human being.
- 25 14. Use of non-steroidal anti-inflammatory substance
which has the ability to inhibit prostaglandin synthesis in
the human being in the manufacture of a pharmaceutical
formulation for the treatment of dementia in a human being
characterized by administering to the human being a thera-
peutic amount of the formulation.
- 30 15. The use as claimed in claim 14 wherein the
substance is a derivative of arylcarboxylic acids, aryl-
alkanoic acids and enolic acids, and therapeutically
acceptable salts thereof.

-16-

16. The use as claimed in claim 15 wherein the aryl-carboxylic acid is a salicylic acid or an anthranilic acid derivative; the arylalkanoic acid is arylacetic, aryl-propionic, heteroarylacetic, indoleacetic or indeneacetic 5 acid; and the enolic acid is pyrazolidinedione or oxicam, and therapeutically acceptable salts thereof.

17. The use as claimed in claim 14 wherein the substance is salicylic acid, acetylsalicylic acid, di-10 flunisal, choline magnesium trisalicylate, salicylate, benorylate, flufenamic acid, mefenamic acid, meclofenamic acid, niflumic acid, diclofenac, fenclofenac, alclofenac, fentiazac, ibuprofen, flurbiprofen, ketoprofen, naproxen, fenoprofen, fenbufen, suprofen, indoprofen, tiaprofenic 15 acid, benoxaprofen, pirprofen, tolmetin, zomepirac, clopinac, indomethacin, sulindac, phenylbutazone, oxyphenbutazone, azapropazone, feprazole, piroxicam, isoxicam or sodoxicam.

20 18. The use as claimed in claim 14 wherein the substance is indomethacin.

1/2




FIG. 1




FIG. 2

SUBSTITUTE SHEET

2/2





FIG. 3

FIG. 4
SUBSTITUTE SHEET.

INTERNATIONAL SEARCH REPORT

International Application No PCT/CA 92/00229

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ^{1b}		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.C1.5 A 61 K 31/00 A 61 K 31/405		
II. FIELDS SEARCHED		
Minimum Documentation Searched ²		
Classification System	Classification Symbols	
Int.C1.5	A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ³		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁴		
Category ⁵	Citation of Document ^{1c} with indication, where appropriate, of the relevant passages ^{1d}	Relevant to Claim No. ^{1d}
X	The Lancet, vol. 335, no. 8696, 28 April 1990, P.L. McGEER et al.: "Anti-inflammatory drugs and Alzheimer disease", page 1037, see the whole document (cited in the application) ---	1-13
X	J.E.F. REYNOLDS et al.: "Martindale - The Extra Pharmacopoeia", 28th edition, 1982, Pharmaceutical Press, London, GB, pages 234-282: "Aspirin and similar analgesic and anti-inflammatory agents", see the whole document ---	8-13
* Special categories of cited documents: ^{1e} "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason has specified "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 10-11-1992	Date of Mailing of this International Search Report 07.12.92	
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer <i>DAGMAR HESCH</i>	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	Neurologia, vol. 7, no. 2, February 1992, J.J. POZA-ALDEA et al.: "Consumo cronico de AINE gamma enfermedad de Alzheimer", page 85, see the whole document ---	1-13
A	Neurology, vol. 40, November 1990, G.A. BROE et al.: "A case-control study of Alzheimer's disease in Australia", pages 1698-1707, see the whole document -----	1-13

INTERNATIONAL SEARCH REPORT11. International application No.
PCT/CA92/00229**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: X
because they relate to subject matter not required to be searched by this Authority, namely:
ALTHOUGH CLAIMS 1-7 ARE DIRECTED TOWARDS A METHOD OF TREATMENT OF THE HUMAN BODY, THE SEARCH HAS BEEN CARRIED OUT AND BASED ON THE ALLEGED EFFECTS OF THE COMPOSITIONS.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

**IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image
problems checked, please do not report these problems to
the IFW Image Problem Mailbox.**